Overview

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

Status:
Not yet recruiting
Trial end date:
2025-01-10
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche